Quantcast
Tag archive for ‘Novartis’
By The Dispatch On Tuesday, July 29th, 2014
0 Comments

Bexsero, meningitis B vaccine vaccination campaign results released

Novartis has announced the initial results of a large-scale vaccination campaign with Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) to help protect against meningitis B within the Saguenay-Lac-Saint-Jean More...

By The Dispatch On Tuesday, June 17th, 2014
1 Comment

Novartis seeks FDA approval for meningitis B vaccine, Bexsero

Basel, June 17, 2014 – Novartis announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero® (Multicomponent More...

By The Dispatch On Monday, April 7th, 2014
0 Comments

Bexsero, meningitis B vaccine, receives FDA Breakthrough Therapy designation

PRESS RELEASE Novartis announced today that Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) has received a Breakthrough Therapy designation from the United States Food and Drug Administration More...

By Robert Herriman On Saturday, November 23rd, 2013
2 Comments

What is Bexsero? How common is meningococcal disease serogroup B?

With the eighth case of meningococcal meningitis confirmed at Princeton University yesterday, and at least seven confirmed as Neisseria meningitis serotype B (MenB) with the most recent still pending, health officials More...

By Robert Herriman On Thursday, January 24th, 2013
1 Comment

Bexsero, first Meningitis B vaccine, receives European Commission approval

Photo/CDC/ Debora Cartagena Switzerland-based pharmaceutical and health care company, Novartis announced this week that it’s Meningitis B vaccine, Bexsero, has received approval from the European Commission More...


Recent Posts

January 22, 2020, Comments Off on

January 22, 2020, Comments Off on

January 22, 2020, Comments Off on

DISPATCH BLOGS

Splash Page logo 300x146 Today in History